BEIJING, China – April 24, 2020 – Analog Devices, Inc. (Nasdaq: ADI) and the ADI Foundation, which aims to create a more sustainable future, announce a $500,000 donation to support funding by Dr. Research conducted by the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH), led by Mark Poznansky.
The funding will directly support the development of VIC’s vaccine and point-of-care virus testing technologies for COVID-19, which are critical for gradually opening up the economy and improving the safety of health care workers and patients. Analog Devices and VIC are working closely together to conduct trials on the development and deployment of two new testing technologies to identify and confirm individuals with an immune response to COVID-19 who also test negative for the virus. ADI and VIC will also leverage ADI’s testing technology to provide rapid-care testing and real-time remote vital signs monitoring for COVID-19 patients in isolation.
“ADI is very proud to partner with the Massachusetts General Hospital Vaccine and Immunotherapy Center, which has been working hard to develop the testing solutions needed to identify COVID-19 in individuals and slow the spread of the virus,” said Vincent Roche, President and CEO of ADI. This well-known medical research institution is our best partner in the fight against the new crown pneumonia epidemic, and we look forward to using the detection technology in the testing and monitoring of patients with new coronary pneumonia through the joint efforts of both parties.”
Poznansky, MD, associate professor of medicine at Harvard Medical School and attending physician in general and transplant infectious diseases at MGH, said: “We know that many patients who have contracted Covid-19 remain undiagnosed by testing. In addition, there are many people who may have been infected, But because they are asymptomatic, they don’t know. Confirming negative immunization and virus tests is critical to progressively opening up key areas of society, identifying people who are relatively safe to communicate with each other, and those who should continue to isolate.”
MGH VIC was established in 2008 to accelerate the translation of laboratory findings into novel, safe, broadly applicable, and cost-effective vaccines and treatments for the prevention and treatment of various forms of cancer, infectious diseases and immune-mediated diseases . VIC currently has nine medical products in development, and three have entered human testing.
The Links: G057VN01 V1 1DI300ZN-120